1
|
Krstulović L, Mišković Špoljarić K, Rastija V, Filipović N, Bajić M, Glavaš-Obrovac L. Novel 1,2,3-Triazole-Containing Quinoline-Benzimidazole Hybrids: Synthesis, Antiproliferative Activity, In Silico ADME Predictions, and Docking. Molecules 2023; 28:6950. [PMID: 37836794 PMCID: PMC10574761 DOI: 10.3390/molecules28196950] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/15/2023] [Revised: 10/03/2023] [Accepted: 10/04/2023] [Indexed: 10/15/2023] Open
Abstract
The newly synthesized quinoline-benzimidazole hybrids containing two types of triazole-methyl-phenoxy linkers were characterized via NMR and elemental analysis. Additional derivatization was achieved by introducing bromine at the C-2 position of the phenoxy core. These novel hybrids were tested for their effects on the growth of the non-tumor cell line MRC-5 (human fetal lung fibroblasts), leukemia and lymphoma cell lines: Hut78, THP-1 and HL-60, and carcinoma cell lines: HeLa and CaCo-2. The results obtained, presented as the concentration that achieves 50% inhibition of cell growth (IC50 value), show that the compounds tested affect tumor cell growth differently depending on the cell line and the dose applied (IC50 ranged from 0.2 to >100 µM). The quinoline-benzimidazole hybrids tested, including 7-chloro-4-(4-{[4-(5-methoxy-1H-1,3-benzo[d]imidazol-2-yl)phenoxy]methyl}-1H-1,2,3-triazol-1-yl)quinoline 9c, 2-(3-bromo-4-{[1-(7-chloroquinolin-4-yl)-1H-1,2,3-triazol-4-yl]methoxy}phenyl)-N-propyl-1H-benzo[d]imidazol-5-carboximidamide trihydrochloride 10e, 2-{4-[(1-{2-[(7-chloroquinolin-4-yl)amino]ethyl}-1H-1,2,3-triazol-4-yl)methoxy]phenyl}-N-propyl-1H-benzo[d]imidazol-5-carboximidamide trihydrochloride 14e and 2-{3-bromo-4-[(1-{2-[(7-chloroquinolin-4-yl)amino]ethyl}-1H-1,2,3-triazol-4-yl)methoxy]phenyl}-N-propyl-1H-benzo[d]imidazol-5-carboximidamide trihydrochloride 15e, arrested the cell cycle of lymphoma (HuT78) cells. The calculated ADMET properties showed that the synthesized compounds violated at most two of Lipinski's rules, making them potential drug candidates, but mainly for parenteral use due to low gastrointestinal absorption. The quinoline-benzimidazole hybrid 14e, which was shown to be a potent and selective inhibitor of lymphoma cell line growth, obtained the highest binding energy (-140.44 kcal/mol), by docking to the TAO2 kinase domain (PDB: 2GCD).
Collapse
Affiliation(s)
- Luka Krstulović
- Department of Chemistry and Biochemistry, Faculty of Veterinary Medicine, University of Zagreb, Heinzelova 55, 10000 Zagreb, Croatia;
| | - Katarina Mišković Špoljarić
- Department of Medicinal Chemistry, Biochemistry and Clinical Chemistry, Faculty of Medicine, Josip Juraj Strossmayer University of Osijek, Josipa Huttlera 4, 31000 Osijek, Croatia;
| | - Vesna Rastija
- Faculty of Agrobiotechnical Sciences Osijek, Josip Juraj Strossmayer University of Osijek, Vladimira Preloga 1, 31000 Osijek, Croatia;
| | - Nikolina Filipović
- Department of Chemistry, Josip Juraj Strossmayer University of Osijek, Cara Hadrijana 8a, 31000 Osijek, Croatia;
| | - Miroslav Bajić
- Department of Chemistry and Biochemistry, Faculty of Veterinary Medicine, University of Zagreb, Heinzelova 55, 10000 Zagreb, Croatia;
| | - Ljubica Glavaš-Obrovac
- Department of Medicinal Chemistry, Biochemistry and Clinical Chemistry, Faculty of Medicine, Josip Juraj Strossmayer University of Osijek, Josipa Huttlera 4, 31000 Osijek, Croatia;
| |
Collapse
|
2
|
Sharma B, Agarwal A, Awasthi SK. Is structural hybridization invoking new dimensions for antimalarial drug discovery research? RSC Med Chem 2023; 14:1227-1253. [PMID: 37484560 PMCID: PMC10357931 DOI: 10.1039/d3md00083d] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/17/2023] [Accepted: 05/01/2023] [Indexed: 07/25/2023] Open
Abstract
Despite effective prevention methods, malaria is a devastating, persistent infection caused by protozoal parasites that result in nearly half a million fatalities annually. Any progress made thus far in the eradication of the disease is jeopardized by the expansion of malaria parasites that have evolved to become resistant to a wide range of drugs, including first-line therapy. To surmount this significant obstacle, it is necessary to develop newly synthesized drugs with multiple modes of action that may have a novel target in various stages of Plasmodium parasite development and this is made possible by the hybridization concept. Hybridization is the combination of at least two diverse pharmacophore units with some linkers bringing about a single molecule with a diverse mode of action. It intensifies a drug's physiological and chemical characteristics, such as absorption, cellular target contact, metabolism, excretion, distribution, and toxicity. This review article outlines the currently published most potent hybrid drugs against the Plasmodium species.
Collapse
Affiliation(s)
- Bhawana Sharma
- Chemical Biology Laboratory, Department of Chemistry, University of Delhi Delhi-110007 India
| | - Alka Agarwal
- Department of Medicinal Chemistry, Institute of Medical Sciences, Banaras Hindu University Varanasi-221005 Uttar Pradesh India
| | - Satish Kumar Awasthi
- Chemical Biology Laboratory, Department of Chemistry, University of Delhi Delhi-110007 India
| |
Collapse
|
3
|
Burns AL, Sleebs BE, Gancheva M, McLean KT, Siddiqui G, Venter H, Beeson JG, O’Handley R, Creek DJ, Ma S, Frölich S, Goodman CD, McFadden GI, Wilson DW. Targeting malaria parasites with novel derivatives of azithromycin. Front Cell Infect Microbiol 2022; 12:1063407. [PMID: 36530422 PMCID: PMC9748569 DOI: 10.3389/fcimb.2022.1063407] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/07/2022] [Accepted: 11/09/2022] [Indexed: 12/02/2022] Open
Abstract
Introduction The spread of artemisinin resistant Plasmodium falciparum parasites is of global concern and highlights the need to identify new antimalarials for future treatments. Azithromycin, a macrolide antibiotic used clinically against malaria, kills parasites via two mechanisms: 'delayed death' by inhibiting the bacterium-like ribosomes of the apicoplast, and 'quick-killing' that kills rapidly across the entire blood stage development. Methods Here, 22 azithromycin analogues were explored for delayed death and quick-killing activities against P. falciparum (the most virulent human malaria) and P. knowlesi (a monkey parasite that frequently infects humans). Results Seventeen analogues showed improved quick-killing against both Plasmodium species, with up to 38 to 20-fold higher potency over azithromycin after less than 48 or 28 hours of treatment for P. falciparum and P. knowlesi, respectively. Quick-killing analogues maintained activity throughout the blood stage lifecycle, including ring stages of P. falciparum parasites (<12 hrs treatment) and were >5-fold more selective against P. falciparum than human cells. Isopentenyl pyrophosphate supplemented parasites that lacked an apicoplast were equally sensitive to quick-killing analogues, confirming that the quick killing activity of these drugs was not directed at the apicoplast. Further, activity against the related apicoplast containing parasite Toxoplasma gondii and the gram-positive bacterium Streptococcus pneumoniae did not show improvement over azithromycin, highlighting the specific improvement in antimalarial quick-killing activity. Metabolomic profiling of parasites subjected to the most potent compound showed a build-up of non-haemoglobin derived peptides that was similar to chloroquine, while also exhibiting accumulation of haemoglobin-derived peptides that was absent for chloroquine treatment. Discussion The azithromycin analogues characterised in this study expand the structural diversity over previously reported quick-killing compounds and provide new starting points to develop azithromycin analogues with quick-killing antimalarial activity.
Collapse
Affiliation(s)
- Amy L. Burns
- Research Centre for Infectious Diseases, School of Biological Sciences, the University of Adelaide, Adelaide, SA, Australia,School of Science and Technology, the University of New England, Armidale, NSW, Australia
| | - Brad E. Sleebs
- ACRF Chemical Biology Division, Walter and Eliza Hall Institute of Medical Research, Parkville, VIC, Australia,Department of Medical Biology, University of Melbourne, Parkville, VIC, Australia
| | - Maria Gancheva
- Research Centre for Infectious Diseases, School of Biological Sciences, the University of Adelaide, Adelaide, SA, Australia
| | - Kimberley T. McLean
- Research Centre for Infectious Diseases, School of Biological Sciences, the University of Adelaide, Adelaide, SA, Australia
| | - Ghizal Siddiqui
- Drug Delivery Disposition and Dynamics, Monash University, Parkville, VIC, Australia
| | - Henrietta Venter
- Health and Biomedical Innovation, Clinical and Health Sciences, University of South Australia, Adelaide, SA, Australia
| | - James G. Beeson
- Healthy Mothers, Healthy Babies Program, Burnet Institute, Melbourne, VIC, Australia,Department of Medicine, University of Melbourne, Parkville, VIC, Australia,Central Clinical School, Monash University, Melbourne, Vic, Australia,Department of Microbiology, Monash University, Melbourne, Vic, Australia
| | - Ryan O’Handley
- School of Animal and Veterinary Science, University of Adelaide, Adelaide, SA, Australia,Australian Centre for Antimicrobial Resistance Ecology, The University of Adelaide, Adelaide, SA, Australia
| | - Darren J. Creek
- Drug Delivery Disposition and Dynamics, Monash University, Parkville, VIC, Australia
| | - Shutao Ma
- Department of Medicinal Chemistry, Key Laboratory of Chemical Biology, Ministry of Education, School of Pharmaceutical Sciences, Shandong University, Jinan, China
| | - Sonja Frölich
- Research Centre for Infectious Diseases, School of Biological Sciences, the University of Adelaide, Adelaide, SA, Australia
| | | | | | - Danny W. Wilson
- Research Centre for Infectious Diseases, School of Biological Sciences, the University of Adelaide, Adelaide, SA, Australia,Healthy Mothers, Healthy Babies Program, Burnet Institute, Melbourne, VIC, Australia,Australian Centre for Antimicrobial Resistance Ecology, The University of Adelaide, Adelaide, SA, Australia,*Correspondence: Danny W. Wilson,
| |
Collapse
|
4
|
Poje G, Pessanha de Carvalho L, Held J, Moita D, Prudêncio M, Perković I, Tandarić T, Vianello R, Rajić Z. Design and synthesis of harmiquins, harmine and chloroquine hybrids as potent antiplasmodial agents. Eur J Med Chem 2022; 238:114408. [DOI: 10.1016/j.ejmech.2022.114408] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/13/2022] [Revised: 04/07/2022] [Accepted: 04/20/2022] [Indexed: 01/12/2023]
|
5
|
Silva Neto GJ, Silva LR, Omena RJMD, Aguiar ACC, Annunciato Y, Rosseto B, Gazarini ML, Heimfarth L, Quintans-Júnior LJ, Ferreira E, Meneghetti MR. Dual Quinoline-Hybrid Compounds with Antimalarial Activity Against Plasmodium falciparum Parasites. NEW J CHEM 2022. [DOI: 10.1039/d1nj05598d] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
Although we have at our disposal relatively low-cost drugs that can be prescribed for the treatment of malaria, the prevalence of resistant strains of the causative parasite has required the...
Collapse
|
6
|
Uddin A, Chawla M, Irfan I, Mahajan S, Singh S, Abid M. Medicinal chemistry updates on quinoline- and endoperoxide-based hybrids with potent antimalarial activity. RSC Med Chem 2021; 12:24-42. [PMID: 34046596 PMCID: PMC8132992 DOI: 10.1039/d0md00244e] [Citation(s) in RCA: 16] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/14/2020] [Accepted: 10/19/2020] [Indexed: 02/01/2023] Open
Abstract
The resistance of conventional antimalarial drugs against the malarial parasite continues to pose a challenge to control the disease. The indiscriminate exploitation of the available antimalarials has resulted in increasing treatment failures, which urges on the search for novel lead molecules. Artemisinin-based combination therapy (ACT) is the current WHO-recommended first-line treatment for the majority of malaria cases. Hybrid molecules offer a newer strategy for the development of next-generation antimalarial drugs. These comprise molecules, each with an individual pharmacological activity, linked together into a single hybrid molecule. This approach has been utilized by several research groups to develop molecules with potent antimalarial activity. In this review, we provide an overview of the pivotal roles of quinoline- and endoperoxide-based hybrids as inhibitors of the life-cycle progression of Plasmodium. Based on the exhaustive literature reports, we have collated the structural and functional analyses of quinoline- and endoperoxide-based hybrid molecules that show potency equal to or greater than those of the individual compounds, offering an effective therapeutics option for clinical use.
Collapse
Affiliation(s)
- Amad Uddin
- Medicinal Chemistry Laboratory, Department of Biosciences, Jamia Millia Islamia Jamia Nagar New Delhi-110025 India +91 8750295095
- Special Centre for Molecular Medicine, Jawaharlal Nehru University New Delhi-110067 India
| | - Meenal Chawla
- Medicinal Chemistry Laboratory, Department of Biosciences, Jamia Millia Islamia Jamia Nagar New Delhi-110025 India +91 8750295095
| | - Iram Irfan
- Medicinal Chemistry Laboratory, Department of Biosciences, Jamia Millia Islamia Jamia Nagar New Delhi-110025 India +91 8750295095
| | - Shubhra Mahajan
- Medicinal Chemistry Laboratory, Department of Biosciences, Jamia Millia Islamia Jamia Nagar New Delhi-110025 India +91 8750295095
| | - Shailja Singh
- Special Centre for Molecular Medicine, Jawaharlal Nehru University New Delhi-110067 India
| | - Mohammad Abid
- Medicinal Chemistry Laboratory, Department of Biosciences, Jamia Millia Islamia Jamia Nagar New Delhi-110025 India +91 8750295095
| |
Collapse
|
7
|
Peric M, Pešić D, Alihodžić S, Fajdetić A, Herreros E, Gamo FJ, Angulo-Barturen I, Jiménez-Díaz MB, Ferrer-Bazaga S, Martínez MS, Gargallo-Viola D, Mathis A, Kessler A, Banjanac M, Padovan J, Bencetić Mihaljević V, Munic Kos V, Bukvić M, Eraković Haber V, Spaventi R. A novel class of fast-acting antimalarial agents: Substituted 15-membered azalides. Br J Pharmacol 2020; 178:363-377. [PMID: 33085774 PMCID: PMC9328652 DOI: 10.1111/bph.15292] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/13/2020] [Revised: 09/01/2020] [Accepted: 10/08/2020] [Indexed: 12/18/2022] Open
Abstract
Background and Purpose Efficacy of current antimalarial treatments is declining as a result of increasing antimalarial drug resistance, so new and potent antimalarial drugs are urgently needed. Azithromycin, an azalide antibiotic, was found useful in malaria therapy, but its efficacy in humans is low. Experimental Approach Four compounds belonging to structurally different azalide classes were tested and their activities compared to azithromycin and chloroquine. in vitro evaluation included testing against sensitive and resistant Plasmodium falciparum, cytotoxicity against HepG2 cells, accumulation and retention in human erythrocytes, antibacterial activity, and mode of action studies (delayed death phenotype and haem polymerization). in vivo assessment enabled determination of pharmacokinetic profiles in mice, rats, dogs, and monkeys and in vivo efficacy in a humanized mouse model. Key Results Novel fast‐acting azalides were highly active in vitro against P. falciparum strains exhibiting various resistance patterns, including chloroquine‐resistant strains. Excellent antimalarial activity was confirmed in a P. falciparum murine model by strong inhibition of haemozoin‐containing trophozoites and quick clearance of parasites from the blood. Pharmacokinetic analysis revealed that compounds are metabolically stable and have moderate oral bioavailability, long half‐lives, low clearance, and substantial exposures, with blood cells as the preferred compartment, especially infected erythrocytes. Fast anti‐plasmodial action is achieved by the high accumulation into infected erythrocytes and interference with parasite haem polymerization, a mode of action different from slow‐acting azithromycin. Conclusion and Implications The hybrid derivatives described here represent excellent antimalarial drug candidates with the potential for clinical use in malaria therapy.
Collapse
Affiliation(s)
- Mihaela Peric
- GlaxoSmithKline Research Centre Zagreb Ltd., Zagreb, Croatia.,Center for Translational and Clinical Research, Department for Intercellular Communication, University of Zagreb School of Medicine, Zagreb, Croatia
| | - Dijana Pešić
- GlaxoSmithKline Research Centre Zagreb Ltd., Zagreb, Croatia.,Fidelta Ltd., Zagreb, Croatia
| | - Sulejman Alihodžić
- GlaxoSmithKline Research Centre Zagreb Ltd., Zagreb, Croatia.,Fidelta Ltd., Zagreb, Croatia
| | - Andrea Fajdetić
- GlaxoSmithKline Research Centre Zagreb Ltd., Zagreb, Croatia.,Fidelta Ltd., Zagreb, Croatia
| | - Esperanza Herreros
- GlaxoSmithKline, Tres Cantos Medicines Development Campus, Diseases of the Developing World, Tres Cantos (Madrid), Spain.,Medicines for Malaria Venture, Geneva 15, Switzerland
| | - Francisco Javier Gamo
- GlaxoSmithKline, Tres Cantos Medicines Development Campus, Diseases of the Developing World, Tres Cantos (Madrid), Spain
| | - Iñigo Angulo-Barturen
- GlaxoSmithKline, Tres Cantos Medicines Development Campus, Diseases of the Developing World, Tres Cantos (Madrid), Spain.,The Art of Discovery, Bizkaia, Basque Country, Spain
| | - María Belén Jiménez-Díaz
- GlaxoSmithKline, Tres Cantos Medicines Development Campus, Diseases of the Developing World, Tres Cantos (Madrid), Spain.,The Art of Discovery, Bizkaia, Basque Country, Spain
| | - Santiago Ferrer-Bazaga
- GlaxoSmithKline, Tres Cantos Medicines Development Campus, Diseases of the Developing World, Tres Cantos (Madrid), Spain
| | - María S Martínez
- GlaxoSmithKline, Tres Cantos Medicines Development Campus, Diseases of the Developing World, Tres Cantos (Madrid), Spain
| | - Domingo Gargallo-Viola
- GlaxoSmithKline, Tres Cantos Medicines Development Campus, Diseases of the Developing World, Tres Cantos (Madrid), Spain.,ABAC Therapeutics, Barcelona, Spain
| | - Amanda Mathis
- GlaxoSmithKline, Research Triangle Park, North Carolina, USA.,BioCryst Pharmaceuticals, Durham, North Carolina, USA
| | - Albane Kessler
- GlaxoSmithKline, Tres Cantos Medicines Development Campus, Diseases of the Developing World, Tres Cantos (Madrid), Spain
| | - Mihailo Banjanac
- GlaxoSmithKline Research Centre Zagreb Ltd., Zagreb, Croatia.,Fidelta Ltd., Zagreb, Croatia
| | - Jasna Padovan
- GlaxoSmithKline Research Centre Zagreb Ltd., Zagreb, Croatia.,Fidelta Ltd., Zagreb, Croatia
| | | | - Vesna Munic Kos
- GlaxoSmithKline Research Centre Zagreb Ltd., Zagreb, Croatia.,Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden
| | - Mirjana Bukvić
- GlaxoSmithKline Research Centre Zagreb Ltd., Zagreb, Croatia.,Fidelta Ltd., Zagreb, Croatia
| | - Vesna Eraković Haber
- GlaxoSmithKline Research Centre Zagreb Ltd., Zagreb, Croatia.,Fidelta Ltd., Zagreb, Croatia
| | - Radan Spaventi
- GlaxoSmithKline Research Centre Zagreb Ltd., Zagreb, Croatia.,Triadelta Partners Ltd, Zagreb, Croatia
| |
Collapse
|
8
|
Ishmail FZ, Melis DR, Mbaba M, Smith GS. Diversification of quinoline-triazole scaffolds with CORMs: Synthesis, in vitro and in silico biological evaluation against Plasmodium falciparum. J Inorg Biochem 2020; 215:111328. [PMID: 33340802 DOI: 10.1016/j.jinorgbio.2020.111328] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/15/2020] [Revised: 11/25/2020] [Accepted: 12/01/2020] [Indexed: 10/22/2022]
Abstract
A discrete series of tricarbonyl manganese and rhenium complexes conjugated to a quinoline-triazole hybrid scaffold were synthesised and their inhibitory activities evaluated against Plasmodium falciparum. In general, the complexes show moderate activity with improved inhibitory activities for the photoactivatable manganese(I) tricarbonyl complexes in the malaria parasite. All complexes are active in the dark against the NF54 CQS (chloroquine-sensitive) and K1 MDR (multidrug-resistant) strains of Plasmodium falciparum, with IC50 values in the low micromolar range. Of significance, the complexes retain their activity in the MDR strain with resistance indices ranging between 1.1 and 2.1. The Mn(I) analogues display photodissociation of all three CO ligands upon irradiation at 365 nm. More importantly, the complexes show increased antimalarial activity in vitro upon photoactivation, something not observed by the clinically used reference drug, chloroquine. As a purported mechanism of action, the compounds were evaluated as β-haematin inhibitors. To further understand the interactions of the complexes, in silico hemozoin docking simulations were performed, attesting to the fact that CO-release could be vital for blocking the hemozoin formation pathway. These results show that this strategy may be a valuable, novel route to design antimalarial agents with higher efficacy.
Collapse
Affiliation(s)
- Fatima-Zahra Ishmail
- Department of Chemistry, University of Cape Town, Rondebosch, Cape Town 7700, South Africa
| | - Diana R Melis
- Department of Chemistry, University of Cape Town, Rondebosch, Cape Town 7700, South Africa
| | - Mziyanda Mbaba
- Department of Chemistry, University of Cape Town, Rondebosch, Cape Town 7700, South Africa
| | - Gregory S Smith
- Department of Chemistry, University of Cape Town, Rondebosch, Cape Town 7700, South Africa.
| |
Collapse
|
9
|
Burns AL, Sleebs BE, Siddiqui G, De Paoli AE, Anderson D, Liffner B, Harvey R, Beeson JG, Creek DJ, Goodman CD, McFadden GI, Wilson DW. Retargeting azithromycin analogues to have dual-modality antimalarial activity. BMC Biol 2020; 18:133. [PMID: 32993629 PMCID: PMC7526119 DOI: 10.1186/s12915-020-00859-4] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/09/2020] [Accepted: 08/28/2020] [Indexed: 11/22/2022] Open
Abstract
BACKGROUND Resistance to front-line antimalarials (artemisinin combination therapies) is spreading, and development of new drug treatment strategies to rapidly kill Plasmodium spp. malaria parasites is urgently needed. Azithromycin is a clinically used macrolide antibiotic proposed as a partner drug for combination therapy in malaria, which has also been tested as monotherapy. However, its slow-killing 'delayed-death' activity against the parasite's apicoplast organelle and suboptimal activity as monotherapy limit its application as a potential malaria treatment. Here, we explore a panel of azithromycin analogues and demonstrate that chemical modifications can be used to greatly improve the speed and potency of antimalarial action. RESULTS Investigation of 84 azithromycin analogues revealed nanomolar quick-killing potency directed against the very earliest stage of parasite development within red blood cells. Indeed, the best analogue exhibited 1600-fold higher potency than azithromycin with less than 48 hrs treatment in vitro. Analogues were effective against zoonotic Plasmodium knowlesi malaria parasites and against both multi-drug and artemisinin-resistant Plasmodium falciparum lines. Metabolomic profiles of azithromycin analogue-treated parasites suggested activity in the parasite food vacuole and mitochondria were disrupted. Moreover, unlike the food vacuole-targeting drug chloroquine, azithromycin and analogues were active across blood-stage development, including merozoite invasion, suggesting that these macrolides have a multi-factorial mechanism of quick-killing activity. The positioning of functional groups added to azithromycin and its quick-killing analogues altered their activity against bacterial-like ribosomes but had minimal change on 'quick-killing' activity. Apicoplast minus parasites remained susceptible to both azithromycin and its analogues, further demonstrating that quick-killing is independent of apicoplast-targeting, delayed-death activity. CONCLUSION We show that azithromycin and analogues can rapidly kill malaria parasite asexual blood stages via a fast action mechanism. Development of azithromycin and analogues as antimalarials offers the possibility of targeting parasites through both a quick-killing and delayed-death mechanism of action in a single, multifactorial chemotype.
Collapse
Affiliation(s)
- Amy L Burns
- Research Centre for Infectious Diseases, School of Biological Sciences, The University of Adelaide, Adelaide, 5005, Australia
| | - Brad E Sleebs
- Walter and Eliza Hall Institute of Medical Research, Melbourne, Victoria, 3050, Australia
- Department of Medical Biology, University of Melbourne, Melbourne, Victoria, 3050, Australia
| | - Ghizal Siddiqui
- Monash Institute of Pharmaceutical Sciences, Monash University, Melbourne, Victoria, 3052, Australia
| | - Amanda E De Paoli
- Monash Institute of Pharmaceutical Sciences, Monash University, Melbourne, Victoria, 3052, Australia
| | - Dovile Anderson
- Monash Institute of Pharmaceutical Sciences, Monash University, Melbourne, Victoria, 3052, Australia
| | - Benjamin Liffner
- Research Centre for Infectious Diseases, School of Biological Sciences, The University of Adelaide, Adelaide, 5005, Australia
| | - Richard Harvey
- Research Centre for Infectious Diseases, School of Biological Sciences, The University of Adelaide, Adelaide, 5005, Australia
| | - James G Beeson
- Burnet Institute, Melbourne, Victoria, 3004, Australia
- Department of Medicine, University of Melbourne, Melbourne, Australia
- Central Clinical School and Department of Microbiology, Monash University, Melbourne, Australia
| | - Darren J Creek
- Monash Institute of Pharmaceutical Sciences, Monash University, Melbourne, Victoria, 3052, Australia
| | - Christopher D Goodman
- School of Biosciences, University of Melbourne, Melbourne, Victoria, 3010, Australia
| | - Geoffrey I McFadden
- School of Biosciences, University of Melbourne, Melbourne, Victoria, 3010, Australia
| | - Danny W Wilson
- Research Centre for Infectious Diseases, School of Biological Sciences, The University of Adelaide, Adelaide, 5005, Australia.
- Burnet Institute, Melbourne, Victoria, 3004, Australia.
| |
Collapse
|
10
|
Janas A, Pecyna P, Gajecka M, Bartl F, Przybylski P. Synthesis and Antibacterial Activity of New
N
‐Alkylammonium and Carbonate‐Triazole Derivatives within Desosamine of 14‐ and 15‐Membered Lactone Macrolides. ChemMedChem 2020; 15:1529-1551. [DOI: 10.1002/cmdc.202000273] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/24/2020] [Revised: 05/21/2020] [Indexed: 02/03/2023]
Affiliation(s)
- Anna Janas
- Faculty of ChemistryAdam Mickiewicz University Uniwersytetu Poznańskiego 8 61-614 Poznań Poland
| | - Paulina Pecyna
- Chair and Department of Genetics and Pharmaceutical MicrobiologyPoznań University of Medical Sciences (PUMS) Święcickiego 4 60-781 Poznań Poland
| | - Marzena Gajecka
- Chair and Department of Genetics and Pharmaceutical MicrobiologyPoznań University of Medical Sciences (PUMS) Święcickiego 4 60-781 Poznań Poland
- Institute of Human GeneticsPolish Academy of Sciences Strzeszynska 32 60-479 Poznań Poland
| | - Franz Bartl
- Lebenswissenschaftliche Fakultät, Institut für Biologie Biophysikalische ChemieHumboldt-Universität zu Berlin Invalidenstrasse 42 10099 Berlin Germany
| | - Piotr Przybylski
- Faculty of ChemistryAdam Mickiewicz University Uniwersytetu Poznańskiego 8 61-614 Poznań Poland
| |
Collapse
|
11
|
Feng LS, Xu Z, Chang L, Li C, Yan XF, Gao C, Ding C, Zhao F, Shi F, Wu X. Hybrid molecules with potential in vitro antiplasmodial and in vivo antimalarial activity against drug-resistant Plasmodium falciparum. Med Res Rev 2019; 40:931-971. [PMID: 31692025 DOI: 10.1002/med.21643] [Citation(s) in RCA: 39] [Impact Index Per Article: 7.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/04/2019] [Revised: 09/16/2019] [Accepted: 10/08/2019] [Indexed: 12/12/2022]
Abstract
Malaria is a tropical disease, leading to around half a million deaths annually. Antimalarials such as quinolines are crucial to fight against malaria, but malaria control is extremely challenged by the limited pipeline of effective pharmaceuticals against drug-resistant strains of Plasmodium falciparum which are resistant toward almost all currently accessible antimalarials. To tackle the growing resistance, new antimalarial drugs are needed urgently. Hybrid molecules which contain two or more pharmacophores have the potential to overcome the drug resistance, and hybridization of quinoline privileged antimalarial building block with other antimalarial pharmacophores may provide novel molecules with enhanced in vitro and in vivo activity against drug-resistant (including multidrug-resistant) P falciparum. In recent years, numerous of quinoline hybrids were developed, and their activities against a panel of drug-resistant P falciparum strains were screened. Some of quinoline hybrids were found to possess promising in vitro and in vivo potency. This review emphasized quinoline hybrid molecules with potential in vitro antiplasmodial and in vivo antimalarial activity against drug-resistant P falciparum, covering articles published between 2010 and 2019.
Collapse
Affiliation(s)
| | - Zhi Xu
- Guizhou University of Traditional Chinese Medicine, Guiyang, China
| | - Le Chang
- WuXi AppTec Co, Ltd, Wuhan, China
| | - Chuan Li
- WuXi AppTec Co, Ltd, Wuhan, China
| | | | | | | | | | - Feng Shi
- WuXi AppTec Co, Ltd, Wuhan, China
| | - Xiang Wu
- WuXi AppTec Co, Ltd, Wuhan, China
| |
Collapse
|
12
|
Janas A, Przybylski P. 14- and 15-membered lactone macrolides and their analogues and hybrids: structure, molecular mechanism of action and biological activity. Eur J Med Chem 2019; 182:111662. [DOI: 10.1016/j.ejmech.2019.111662] [Citation(s) in RCA: 35] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/10/2019] [Revised: 08/12/2019] [Accepted: 08/29/2019] [Indexed: 11/15/2022]
|
13
|
Marella A, Verma G, Shaquiquzzaman M, Khan MF, Akhtar W, Alam MM. Malaria Hybrids: A Chronological Evolution. Mini Rev Med Chem 2019; 19:1144-1177. [PMID: 30887923 DOI: 10.2174/1389557519666190315100027] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/21/2017] [Revised: 05/27/2018] [Accepted: 11/03/2018] [Indexed: 01/13/2023]
Abstract
Malaria, an upsetting malaise caused by a diverse class of Plasmodium species affects about 40% of the world's population. The distress associated with it has reached colossal scales owing to the development of resistance to most of the clinically available agents. Hence, the search for newer molecules for malaria treatment and cure is an incessant process. After the era of a single molecule for malaria treatment ended, there was an advent of combination therapy. However, lately there had been reports of the development of resistance to many of these agents as well. Subsequently, at present most of the peer groups working on malaria treatment aim to develop novel molecules, which may act on more than one biological processes of the parasite life cycle, and these scaffolds have been aptly termed as Hybrid Molecules or Double Drugs. These molecules may hold the key to hitherto unknown ways of showing a detrimental effect on the parasite. This review enlists a few of the recent advances made in malaria treatment by these hybrid molecules in a sequential manner.
Collapse
Affiliation(s)
| | - Garima Verma
- Department of Pharmaceutical Chemistry, School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi - 110062, India
| | - Md Shaquiquzzaman
- Department of Pharmaceutical Chemistry, School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi - 110062, India
| | - Md Faraz Khan
- Department of Pharmaceutical Chemistry, School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi - 110062, India
| | - Wasim Akhtar
- Department of Pharmaceutical Chemistry, School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi - 110062, India
| | - Md Mumtaz Alam
- Department of Pharmaceutical Chemistry, School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi - 110062, India
| |
Collapse
|
14
|
Hu YQ, Gao C, Zhang S, Xu L, Xu Z, Feng LS, Wu X, Zhao F. Quinoline hybrids and their antiplasmodial and antimalarial activities. Eur J Med Chem 2017; 139:22-47. [DOI: 10.1016/j.ejmech.2017.07.061] [Citation(s) in RCA: 203] [Impact Index Per Article: 29.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/12/2017] [Revised: 07/24/2017] [Accepted: 07/24/2017] [Indexed: 11/30/2022]
|
15
|
Zhong Z, Du C, Luo Z, Song S, Liao G, Yao J, Goldmann S, Wang Z. Identification, Characterization, Synthesis, and Strategy for Minimization of Potential Impurities Observed in the Synthesis of Solithromycin. Org Process Res Dev 2017. [DOI: 10.1021/acs.oprd.7b00201] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Affiliation(s)
- Zhihong Zhong
- HEC
Research and Development Center, HEC Pharm Group, Dongguan 523871, P. R. China
| | - Chong Du
- HEC
Research and Development Center, HEC Pharm Group, Dongguan 523871, P. R. China
| | - Zhonghua Luo
- HEC
Research and Development Center, HEC Pharm Group, Dongguan 523871, P. R. China
| | - Shuaihua Song
- HEC
Research and Development Center, HEC Pharm Group, Dongguan 523871, P. R. China
| | - Gaohong Liao
- HEC
Research and Development Center, HEC Pharm Group, Dongguan 523871, P. R. China
| | - Jia Yao
- HEC
Research and Development Center, HEC Pharm Group, Dongguan 523871, P. R. China
| | - Siegfried Goldmann
- HEC
Research and Development Center, HEC Pharm Group, Dongguan 523871, P. R. China
| | - Zhongqing Wang
- HEC
Research and Development Center, HEC Pharm Group, Dongguan 523871, P. R. China
- State Key
Laboratory
of Anti-Infective Drug Development, Sunshine Lake Pharma Co., Ltd., Dongguan 523871, P. R. China
| |
Collapse
|
16
|
Shaveta, Mishra S, Singh P. Hybrid molecules: The privileged scaffolds for various pharmaceuticals. Eur J Med Chem 2016; 124:500-536. [PMID: 27598238 DOI: 10.1016/j.ejmech.2016.08.039] [Citation(s) in RCA: 319] [Impact Index Per Article: 39.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/19/2014] [Revised: 07/21/2016] [Accepted: 08/17/2016] [Indexed: 12/22/2022]
Abstract
The practice of polypharmacology is not a new concept but the approaches which are being adopted for administering the two or more drugs together are varied from time to time. Taking two or more drugs simultaneously, co-formulation of two or more active agents in a single tablet and development of hybrid molecular entities capable to modulate multiple targets are the three popular approaches for multidrug therapy. The simultaneous use of more than one drug for the chemotherapy of a single disease demands a lot of patient compliance. Hence the present form of polypharmacology is gaining popularity in the form of hybrid molecules (multiple ligand approach). From the last 1-2 decades, the synthesis of hybrid molecules by the combination of different biologically relevant moieties has been under constant escalation along with their evaluation as diverse range of pharmacological agents and as potent drugs. This review is focused on the biological potential of hybrid molecules with particular mention of those exhibiting anti-fungal, anti-tuberculosis, anti-malarial, anti-inflammatory and anti-cancer activities. A comparison of the drug potency of the hybrid molecules with their individual counterparts is discussed for quantifying the significance of the concept of molecular hybridisation.
Collapse
Affiliation(s)
- Shaveta
- UGC Sponsored Centre for Advanced Studies, Department of Chemistry, Guru Nanak Dev University, Amritsar, 143005, India
| | - Sahil Mishra
- UGC Sponsored Centre for Advanced Studies, Department of Chemistry, Guru Nanak Dev University, Amritsar, 143005, India
| | - Palwinder Singh
- UGC Sponsored Centre for Advanced Studies, Department of Chemistry, Guru Nanak Dev University, Amritsar, 143005, India.
| |
Collapse
|
17
|
Overcoming Chloroquine Resistance in Malaria: Design, Synthesis, and Structure-Activity Relationships of Novel Hybrid Compounds. Antimicrob Agents Chemother 2016; 60:3076-89. [PMID: 26953199 DOI: 10.1128/aac.02476-15] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/13/2015] [Accepted: 03/04/2016] [Indexed: 12/16/2022] Open
Abstract
Resistance to antimalarial therapies, including artemisinin, has emerged as a significant challenge. Reversal of acquired resistance can be achieved using agents that resensitize resistant parasites to a previously efficacious therapy. Building on our initial work describing novel chemoreversal agents (CRAs) that resensitize resistant parasites to chloroquine (CQ), we herein report new hybrid single agents as an innovative strategy in the battle against resistant malaria. Synthetically linking a CRA scaffold to chloroquine produces hybrid compounds with restored potency toward a range of resistant malaria parasites. A preferred compound, compound 35, showed broad activity and good potency against seven strains resistant to chloroquine and artemisinin. Assessment of aqueous solubility, membrane permeability, and in vitro toxicity in a hepatocyte line and a cardiomyocyte line indicates that compound 35 has a good therapeutic window and favorable drug-like properties. This study provides initial support for CQ-CRA hybrid compounds as a potential treatment for resistant malaria.
Collapse
|
18
|
Čikoš A, Ćaleta I, Žiher D, Vine MB, Elenkov IJ, Dukši M, Gembarovski D, Ilijaš M, Dragojević S, Malnar I, Alihodžić S. Structure and conformational analysis of spiroketals from 6-O-methyl-9(E)-hydroxyiminoerythronolide A. Beilstein J Org Chem 2015; 11:1447-57. [PMID: 26425201 PMCID: PMC4578343 DOI: 10.3762/bjoc.11.157] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/13/2015] [Accepted: 07/23/2015] [Indexed: 11/23/2022] Open
Abstract
Three novel spiroketals were prepared by a one-pot transformation of 6-O-methyl-9(E)-hydroxyiminoerythronolide A. We present the formation of a [4.5]spiroketal moiety within the macrolide lactone ring, but also the unexpected formation of a 10-C=11-C double bond and spontaneous change of stereochemistry at position 8-C. As a result, a thermodynamically stable structure was obtained. The structures of two new diastereomeric, unsaturated spiroketals, their configurations and conformations, were determined by means of NMR spectroscopy and molecular modelling. The reaction kinetics and mechanistic aspects of this transformation are discussed. These rearrangements provide a facile synthesis of novel macrolide scaffolds.
Collapse
Affiliation(s)
- Ana Čikoš
- GlaxoSmithKline Research Centre Zagreb Ltd, Prilaz baruna Filipovića 29, 10000 Zagreb, Croatia
| | - Irena Ćaleta
- GlaxoSmithKline Research Centre Zagreb Ltd, Prilaz baruna Filipovića 29, 10000 Zagreb, Croatia
| | - Dinko Žiher
- GlaxoSmithKline Research Centre Zagreb Ltd, Prilaz baruna Filipovića 29, 10000 Zagreb, Croatia
| | - Mark B Vine
- GlaxoSmithKline, New Frontiers Science Park, Harlow, CM19 5AW, United Kingdom
| | - Ivaylo J Elenkov
- GlaxoSmithKline Research Centre Zagreb Ltd, Prilaz baruna Filipovića 29, 10000 Zagreb, Croatia
| | - Marko Dukši
- GlaxoSmithKline Research Centre Zagreb Ltd, Prilaz baruna Filipovića 29, 10000 Zagreb, Croatia
| | - Dubravka Gembarovski
- GlaxoSmithKline Research Centre Zagreb Ltd, Prilaz baruna Filipovića 29, 10000 Zagreb, Croatia
| | - Marina Ilijaš
- GlaxoSmithKline Research Centre Zagreb Ltd, Prilaz baruna Filipovića 29, 10000 Zagreb, Croatia
| | - Snježana Dragojević
- GlaxoSmithKline Research Centre Zagreb Ltd, Prilaz baruna Filipovića 29, 10000 Zagreb, Croatia
| | - Ivica Malnar
- GlaxoSmithKline Research Centre Zagreb Ltd, Prilaz baruna Filipovića 29, 10000 Zagreb, Croatia
| | - Sulejman Alihodžić
- GlaxoSmithKline Research Centre Zagreb Ltd, Prilaz baruna Filipovića 29, 10000 Zagreb, Croatia
| |
Collapse
|
19
|
Saleh YRH, Saadeh HA, Kaur H, Goyal K, Sehgal R, Mubarak MS. The synthesis of novel hybrid compounds containing 5-nitrothiazole moiety as potential antiparasitic agents. MONATSHEFTE FUR CHEMIE 2015. [DOI: 10.1007/s00706-015-1511-y] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
20
|
Studies on antimicrobial effects of four ligands and their transition metal complexes with 8-mercaptoquinoline and pyridine terminal groups. Bioorg Med Chem Lett 2015; 25:1778-1781. [PMID: 25791454 DOI: 10.1016/j.bmcl.2015.02.056] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/29/2014] [Revised: 02/10/2015] [Accepted: 02/20/2015] [Indexed: 11/24/2022]
Abstract
Four types of ligands (Q1-Q4) and their complexes (1-36) with transition metal ions have been synthesized, in which two new complexes (15 and 20) have been prepared and tested. In vitro antimicrobial activities of the ligands and their complexes were investigated against a representative panel of strains including two Gram positive bacteria (Sarcina ureae, Staphylococcus aureus), two Gram negative bacteria (Escherichia coli, Pseudomonas aeruginosa) and three fungi (Aspergillus niger, Saccharomyces cerevisiae, Fusarium oxysporum f. sp. cubense). The relationship between the structure and the antibacterial activities was discussed. Our study results indicated that some compounds have preferred antibacterial activities that may have potential pharmaceutical applications.
Collapse
|
21
|
Tevyashova AN, Olsufyeva EN, Preobrazhenskaya MN. Design of dual action antibiotics as an approach to search for new promising drugs. RUSSIAN CHEMICAL REVIEWS 2015. [DOI: 10.1070/rcr4448] [Citation(s) in RCA: 24] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
|
22
|
Vandekerckhove S, D'hooghe M. Quinoline-based antimalarial hybrid compounds. Bioorg Med Chem 2014; 23:5098-119. [PMID: 25593097 DOI: 10.1016/j.bmc.2014.12.018] [Citation(s) in RCA: 148] [Impact Index Per Article: 14.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/04/2014] [Revised: 12/03/2014] [Accepted: 12/11/2014] [Indexed: 10/24/2022]
Abstract
Quinoline-containing compounds, such as quinine and chloroquine, have a long-standing history as potent antimalarial agents. However, the increasing resistance of the Plasmodium parasite against these drugs and the lack of licensed malaria vaccines have forced chemists to develop synthetic strategies toward novel biologically active molecules. A strategy that has attracted considerable attention in current medicinal chemistry is based on the conjugation of two biologically active molecules into one hybrid compound. Since quinolines are considered to be privileged antimalarial building blocks, the synthesis of quinoline-containing antimalarial hybrids has been elaborated extensively in recent years. This review provides a literature overview of antimalarial hybrid molecules containing a quinoline core, covering publications between 2009 and 2014.
Collapse
Affiliation(s)
- Stéphanie Vandekerckhove
- SynBioC Research Group, Department of Sustainable Organic Chemistry and Technology, Faculty of Bioscience Engineering, Ghent University, Coupure Links 653, B-9000 Ghent, Belgium
| | - Matthias D'hooghe
- SynBioC Research Group, Department of Sustainable Organic Chemistry and Technology, Faculty of Bioscience Engineering, Ghent University, Coupure Links 653, B-9000 Ghent, Belgium.
| |
Collapse
|
23
|
Sangani CB, Makawana JA, Duan YT, Yin Y, Teraiya SB, Thumar NJ, Zhu HL. Design, synthesis and molecular modeling of biquinoline–pyridine hybrids as a new class of potential EGFR and HER-2 kinase inhibitors. Bioorg Med Chem Lett 2014; 24:4472-4476. [DOI: 10.1016/j.bmcl.2014.07.094] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/12/2014] [Revised: 07/29/2014] [Accepted: 07/31/2014] [Indexed: 10/24/2022]
|
24
|
Hall AJ, Chappell MJ, Aston JAD, Ward SA. Reprint of "Pharmacokinetic modelling of the anti-malarial drug artesunate and its active metabolite dihydroartemisinin". COMPUTER METHODS AND PROGRAMS IN BIOMEDICINE 2014; 114:e14-e28. [PMID: 24457047 DOI: 10.1016/j.cmpb.2013.12.001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/06/2012] [Revised: 04/15/2013] [Accepted: 05/15/2013] [Indexed: 06/03/2023]
Abstract
A four compartment mechanistic mathematical model is developed for the pharmacokinetics of the commonly used anti-malarial drug artesunate and its principle metabolite dihydroartemisinin following oral administration of artesunate. The model is structurally unidentifiable unless additional constraints are imposed. Combinations of mechanistically derived constraints are considered to assess their effects on structural identifiability and on model fits. Certain combinations of the constraints give rise to locally or globally identifiable model structures. Initial validation of the model under various combinations of the constraints leading to identifiable model structures was performed against a dataset of artesunate and dihydroartemisinin concentration-time profiles of 19 malaria patients. When all the discussed constraints were imposed on the model, the resulting globally identifiable model structure was found to fit reasonably well to those patients with normal drug absorption profiles. However, there is wide variability in the fitted parameters and further investigation is warranted.
Collapse
Affiliation(s)
- Adam J Hall
- Departments of Mathematics and Statistics, University of Warwick, Gibbet Hill Road, Coventry CV4 7AL, UK.
| | - Michael J Chappell
- School of Engineering, University of Warwick, Gibbet Hill Road, Coventry CV4 7AL, UK
| | - John A D Aston
- Department of Statistics, University of Warwick, Gibbet Hill Road, Coventry CV4 7AL, UK
| | - Stephen A Ward
- Liverpool School of Tropical Medicine, Pembroke Place, Liverpool L3 5QA, UK
| |
Collapse
|
25
|
Design, synthesis and molecular modeling of pyrazole–quinoline–pyridine hybrids as a new class of antimicrobial and anticancer agents. Eur J Med Chem 2014; 76:549-57. [DOI: 10.1016/j.ejmech.2014.01.018] [Citation(s) in RCA: 76] [Impact Index Per Article: 7.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/03/2013] [Revised: 01/07/2014] [Accepted: 01/13/2014] [Indexed: 01/16/2023]
|
26
|
Wang X, Zhang S, Pang Y, Yuan H, Liang X, Zhang J, Wang D, Wang M, Dong Y. Novel macrocyclic molecules based on 12a-N substituted 16-membered azalides and azalactams as potential antifungal agents. Eur J Med Chem 2013; 73:286-94. [PMID: 24469079 DOI: 10.1016/j.ejmech.2013.11.032] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/02/2013] [Revised: 11/19/2013] [Accepted: 11/24/2013] [Indexed: 11/18/2022]
Abstract
Novel macrocyclic molecules comprising sulfonyl and acyl moiety at the position N-12a of 16-membered azalides (6a-n) and azalactams (10a-r) scaffold were synthesized from cyclododecanone 1 as starting material via 5 steps and 4 steps, respectively. The antifungal activity of these compounds against Sclerotinia sclerotiorum, Pyricularia oryzae, Botrytis cinerea, Rhizoctonia solani and Phytophthora capsici were evaluated and found that compounds possessing α-exomethylene (6c, 6d, 6e and 6g) showed antifungal activity comparable to commercial fungicide Chlorothalonil against P. oryzae and compounds possessing p-chlorobenzoyl exhibited enhanced antifungal activity than those with other substituents against S. sclerotiorum, P. oryzae, and B. cinerea. These findings suggested that the α-exomethylene and p-chlorobenzoyl may be two potential pharmacological active groups with antifungal activities.
Collapse
Affiliation(s)
- Xiaolei Wang
- Department of Applied Chemistry, College of Science, China Agricultural University, Beijing 100193, China
| | - Shun Zhang
- Department of Applied Chemistry, College of Science, China Agricultural University, Beijing 100193, China
| | - Yanlong Pang
- Department of Applied Chemistry, College of Science, China Agricultural University, Beijing 100193, China
| | - Huihui Yuan
- Department of Applied Chemistry, College of Science, China Agricultural University, Beijing 100193, China
| | - Xiaomei Liang
- Department of Applied Chemistry, College of Science, China Agricultural University, Beijing 100193, China
| | - Jianjun Zhang
- Department of Applied Chemistry, College of Science, China Agricultural University, Beijing 100193, China
| | - Daoquan Wang
- Department of Applied Chemistry, College of Science, China Agricultural University, Beijing 100193, China
| | - Mingan Wang
- Department of Applied Chemistry, College of Science, China Agricultural University, Beijing 100193, China
| | - Yanhong Dong
- Department of Applied Chemistry, College of Science, China Agricultural University, Beijing 100193, China.
| |
Collapse
|
27
|
Hall AJ, Chappell MJ, Aston JAD, Ward SA. Pharmacokinetic modelling of the anti-malarial drug artesunate and its active metabolite dihydroartemisinin. COMPUTER METHODS AND PROGRAMS IN BIOMEDICINE 2013; 112:1-15. [PMID: 23871681 DOI: 10.1016/j.cmpb.2013.05.010] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/06/2012] [Revised: 04/15/2013] [Accepted: 05/15/2013] [Indexed: 06/02/2023]
Abstract
A four compartment mechanistic mathematical model is developed for the pharmacokinetics of the commonly used anti-malarial drug artesunate and its principle metabolite dihydroartemisinin following oral administration of artesunate. The model is structurally unidentifiable unless additional constraints are imposed. Combinations of mechanistically derived constraints are considered to assess their effects on structural identifiability and on model fits. Certain combinations of the constraints give rise to locally or globally identifiable model structures. Initial validation of the model under various combinations of the constraints leading to identifiable model structures was performed against a dataset of artesunate and dihydroartemisinin concentration-time profiles of 19 malaria patients. When all the discussed constraints were imposed on the model, the resulting globally identifiable model structure was found to fit reasonably well to those patients with normal drug absorption profiles. However, there is wide variability in the fitted parameters and further investigation is warranted.
Collapse
Affiliation(s)
- Adam J Hall
- Departments of Mathematics and Statistics, University of Warwick, Gibbet Hill Road, Coventry CV4 7AL, UK.
| | | | | | | |
Collapse
|
28
|
Kathrotiya HG, Patel MP. Synthesis and identification of β-aryloxyquinoline based diversely fluorine substituted N-aryl quinolone derivatives as a new class of antimicrobial, antituberculosis and antioxidant agents. Eur J Med Chem 2013; 63:675-84. [DOI: 10.1016/j.ejmech.2013.03.017] [Citation(s) in RCA: 30] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/09/2012] [Revised: 12/28/2012] [Accepted: 03/08/2013] [Indexed: 10/27/2022]
|
29
|
Chauhan K, Sharma M, Saxena J, Singh SV, Trivedi P, Srivastava K, Puri SK, Saxena J, Chaturvedi V, Chauhan PM. Synthesis and biological evaluation of a new class of 4-aminoquinoline–rhodanine hybrid as potent anti-infective agents. Eur J Med Chem 2013; 62:693-704. [DOI: 10.1016/j.ejmech.2013.01.017] [Citation(s) in RCA: 36] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/12/2012] [Revised: 01/01/2013] [Accepted: 01/13/2013] [Indexed: 11/25/2022]
|
30
|
Antimalarial C-9 oxime derivatives from desmycosin, produced by click chemistry. J Antibiot (Tokyo) 2012; 66:191-4. [DOI: 10.1038/ja.2012.113] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022]
|
31
|
Abstract
We have synthesized new derivatives of the macrolide antibiotics erythromycin and azithromycin. Novel deoxysugar moieties were attached to these standard antibiotics by biotransformation using a heterologous host. The resulting compounds were tested against several standard laboratory and clinically isolated bacterial strains. In addition, they were also tested in vitro against standard and drug-resistant strains of human malaria parasites (Plasmodium falciparum) and the liver stages of the rodent malaria parasite (Plasmodium berghei). Antibacterial activity of modified erythromycin and azithromycin showed no improvement over the unmodified macrolides, but the modified compounds showed a 10-fold increase in effectiveness after a short-term exposure against blood stages of malaria. The new compounds also remained active against azithromycin-resistant strains of P. falciparum and inhibited growth of liver-stage parasites at concentrations similar to those used for primaquine. Our findings show that malaria parasites have two distinct responses to macrolide antibiotics, one reflecting the prokaryotic origin of the apicoplast and a second, as-yet uncharacterized response that we attribute to the eukaryotic nature of the parasite. This is the first report for macrolides that target two different functions in the Plasmodium parasites.
Collapse
|
32
|
Current world literature. Curr Opin Infect Dis 2012; 25:718-28. [PMID: 23147811 DOI: 10.1097/qco.0b013e32835af239] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|